Loading...

APC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_APC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) APC (filled histogram) or rat IgG2b, κ APC isotype control (open histogram).
  • GK1.5_APC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) APC (filled histogram) or rat IgG2b, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100411 25 µg 32€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100412 100 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  2. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  3. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  4. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  5. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  6. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  7. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  8. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  9. Campisi L, et al. 2022. Nature. 606:945. PubMed
  10. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  11. Simpson AP, et al. 2022. Cell Rep. 40:111099. PubMed
  12. Shi Z, et al. 2022. Br J Pharmacol. 179:5209. PubMed
  13. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  14. TaSli PN, et al. 2022. J Food Biochem. 46:e14393. PubMed
  15. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  16. Gong F, et al. 2023. Adv Healthc Mater. 12:e2201771. PubMed
  17. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  18. Chen X, et al. 2022. J Extracell Vesicles. 11:e12279. PubMed
  19. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  20. Wang R, et al. 2023. Nat Biomed Eng. 7:38. PubMed
  21. Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed
  22. Cousin N, et al. 2022. Cells. 12: . PubMed
  23. Roh YJ, et al. 2023. Lab Anim Res. 39:2. PubMed
  24. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  25. Lee JY, et al. 2023. Cancer Immunol Immunother. :. PubMed
  26. Patton T, et al. 2023. Cell Death Dis. 14:111. PubMed
  27. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  28. Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed
  29. Berube A, et al. 2022. Viruses. 14:. PubMed
  30. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  31. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  32. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  33. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  34. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  35. Fang A, et al. 2022. J Virol. 96:e0105022. PubMed
  36. Dhalech AH, et al. 2022. J Virol. 96:e0123222. PubMed
  37. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  38. McGee MC, et al. 2022. Bio Protoc. 12:. PubMed
  39. Wu R, et al. 2022. Nat Immunol. 23:1536. PubMed
  40. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  41. Wang Y, et al. 2023. J Neuroinflammation. 20:41. PubMed
  42. Guo D, et al. 2023. Cell Biosci. 13:51. PubMed
  43. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  44. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  45. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  46. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  47. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  48. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  49. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  50. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
  51. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  52. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  53. Zhu W, et al. 2021. Onco Targets Ther. 14:2149. PubMed
  54. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  55. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  56. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  57. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  58. Zhang S, et al. 2022. Acta Pharm Sin B. 12:3124. PubMed
  59. Schmidt V, et al. 2021. J Cell Biol. 220:. PubMed
  60. Zhu P, et al. 2012. J Cereb Blood Flow Metab. 0.482638889. PubMed
  61. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  62. Oh DS, et al. 2021. Autophagy. 17:2111. PubMed
  63. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  64. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  65. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  66. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  67. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  68. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  69. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  70. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  71. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  72. Li K, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  74. Hongu T, et al. 2022. Nat Cancer. 3:486. PubMed
  75. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  76. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  77. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  78. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  79. Zhang X, et al. 2020. J Immunol. 205:1743. PubMed
  80. Oghumu S, et al. 2014. Immunology. 143: 109-119. PubMed
  81. Inoue M, et al. 2014. Proc Natl Acad Sci U S A. 111:5295. PubMed
  82. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  83. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  84. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  85. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  86. Yang X, et al. 2019. Oncotarget. 10:4180. PubMed
  87. Khatun A, et al. 2021. J Exp Med. 218:. PubMed
  88. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  89. Shin JE, et al. 2021. Heliyon. 7:e08433. PubMed
  90. Canto F, et al. 2016. Sci Rep. 6:28573. PubMed
  91. Ben-Shaanan T, et al. 2016. Nat Med. 10.1038/nm.4133. PubMed
  92. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  93. Wei SC, et al. 2020. Cancer Discov. . PubMed
  94. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  95. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  96. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  97. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
  98. Uceda-Castro R, et al. 2022. Cell Rep Med. 3:100821. PubMed
  99. Freitas JT, et al. 2021. Pigment Cell Melanoma Res. 34:1084. PubMed
  100. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  101. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  102. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  103. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  104. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  105. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  106. Wu C, et al. 2014. J Mol Cell Cardiol. 76:33. PubMed
  107. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  108. Ng SS, et al. 2020. Nat Immunol. 21:1205. PubMed
  109. Leisegang M, et al. 2016. Clin Cancer Res. 22: 2734 - 2743. PubMed
  110. Li J, et al. 2020. Elife. 9:00. PubMed
  111. Abdul Pari AA, et al. 2020. Cancer Res. 80:2586. PubMed
  112. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  113. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  114. Chisolm DA et al. 2019. Immunity. 51(1):155-168 . PubMed
  115. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  116. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  117. Yang W, et al. 2020. Methods Mol Biol. 2111:91. PubMed
  118. Yang J, et al. 2020. Nature. 586:572. PubMed
  119. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  120. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  121. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  122. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  123. Ren G et al. 2017. Molecular cell. 67(6):1049-1058 . PubMed
  124. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  125. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  126. Tan YY, et al. 2021. Exp Ther Med. 22:1368. PubMed
  127. Zhou Z, et al. 2022. Infect Immun. 90:e0045321. PubMed
  128. Toyama S, et al. 2021. Int J Mol Sci. 22:. PubMed
  129. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  130. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  131. Nakajima-Adachi H, et al. 2017. PLoS One. 12(2):e0172795. PubMed
  132. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  133. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  134. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  135. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  136. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  137. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  138. Li Z, et al. 2021. MBio. 12:e0254221. PubMed
  139. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  140. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  141. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  142. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  143. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  144. Clemens E, et al. 2015. J Immunol. 194:898. PubMed
  145. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  146. Bosnjak B, et al. 2019. Front Immunol. 10:840. PubMed
  147. Zou D, et al. 2020. EBioMedicine. 52:102652. PubMed
  148. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  149. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  150. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  151. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  152. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  153. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  154. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  155. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  156. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  157. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  158. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  159. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  160. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  161. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  162. Zhu S, et al. 2022. EBioMedicine. 80:104060. PubMed
  163. Garcia-Dominguez D, et al. 2022. Front Immunol. 13:948335. PubMed
  164. Yu X, et al. 2013. Cancer Res. 73:2093. PubMed
  165. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  166. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  167. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  168. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  169. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  170. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  171. Kanatsu-Shinohara M, et al. 2022. J Reprod Dev. Online ahead of print. PubMed
  172. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  173. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  174. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  175. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
  176. Montero-Barrera D, et al. 2015. BioMed Res Int. 2015 615865. PubMed
  177. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  178. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  179. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  180. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  181. Lo W, et al. 2014. Elife. 14:1457. PubMed
  182. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  183. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  184. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  185. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  186. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  187. Hosaka K, et al. 2020. Nat Commun. 3.030555556. PubMed
  188. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  189. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  190. Ma C, et al. 2021. Mol Metab. 47:101170. PubMed
  191. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  192. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  193. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  194. Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed
  195. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  196. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  197. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  198. Ando T, et al. 2017. Inflammation. 10.1007/s10753-017-0613-6. PubMed
  199. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  200. Mazumder S, et al. 2021. Heliyon. 7:e08124. PubMed
  201. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  202. Caporarello N, et al. 2022. Nat Commun. 13:4170. PubMed
  203. Schadler K, et al. 2014. Cancer Res. 74:2171. PubMed
  204. L M, et al. 2016. Brain. 139: 1939-1957. PubMed
  205. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  206. Luo Z, et al. 2020. J Virol. 94:00:00. PubMed
  207. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  208. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  209. Albaghdadi AJH, et al. 2019. Sci Rep. 9:6528. PubMed
  210. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  211. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  212. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  213. Yang H, et al. 2022. Viruses. 14:. PubMed
  214. He C, et al. 2021. Immunol Cell Biol. 99:611. PubMed
  215. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  216. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  217. Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed
  218. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
  219. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  220. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  221. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_312696 (BioLegend Cat. No. 100411)
AB_312696 (BioLegend Cat. No. 100412)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account